Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study in in Vitro Fertilisation (IVF) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women undergoing ovarian stimulation for IVF with the following characteristics:~  * Able and willing to sign the Patient Consent Form and adhere to the study visitation schedule~ * \>18 and \<40 years old~ * BMI between 18 and 30 kg/m2~ * less than 3 previously completed IVF cycles (i.e. completed cycle = egg recovery)~ * basal FSH \<10 IU/L and E2 \<80 pg/ml (\~290 pmol/l)~ * Within 12 months of the beginning of the study, uterine cavity consistent with expected normal function as assessed through transvaginal ultrasound, hysterosalpingogram, sonohysterogram or hysteroscopic examination~ * Successful down-regulation performed with a standard GnRH-Agonist long protocol (Criteria for successful down-regulation: endometrial thickness \< 7mm or serum E2 level \<50 pg/ml (\~185 pmol/l).~Exclusion Criteria:~* age \<18 and \>40 years~* primary ovarian failure or women known as poor responders (i.e. requiring more than 225 IU of hMG as a starting dose in previous treatment cycles or having less than 3 oocytes retrieved, or with a pre-ovulatory E2 serum concentration \<500pg/ml (\~1800 pmol/l))~* PCOS~* one or both ovaries inaccessible for oocyte retrieval~* ovarian cysts \>10 mm~* hydrosalpinx that have not been surgically removed or ligated;~* stage 3 or 4 endometriosis~* oocyte donation~* implantation of previously frozen embryos~* patients affected by pathologies associated with any contraindication of being pregnant~* hypersensitivity to the study medication~* abnormal bleeding of undetermined origin~* uncontrolled thyroid or adrenal dysfunction~* neoplasias~* severe impairment of renal and/or hepatic function~* use of concomitant medications that might interfere with study evaluations (e.g. non-study hormonal medications, prostaglandin inhibitors, psychotropic agents)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- hMG-IBSA (Type: EXPERIMENTAL): New hMG preparation.
- Menopur (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).